Cargando…
Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity
Doxorubicin (DOX) has limited efficacy in colorectal cancer due to multi-drug resistance. Resveratrol (RES) and didox (DID) are polyhydroxyphenols with potential chemosensitizing effects. Herein, we assessed the chemomodulatory effects of RES and DID to DOX in colorectal cancer cells. Equitoxic comb...
Autores principales: | Khaleel, Sahar A., Al-Abd, Ahmed M., Ali, Azza A., Abdel-Naim, Ashraf B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107943/ https://www.ncbi.nlm.nih.gov/pubmed/27841296 http://dx.doi.org/10.1038/srep36855 |
Ejemplares similares
-
The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines
por: Abdel-Latif, Ghada A., et al.
Publicado: (2015) -
The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML
por: Cook, Guerry J., et al.
Publicado: (2014) -
The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells
por: Asperti, Michela, et al.
Publicado: (2019) -
Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox
por: Inayat, Mohammed S, et al.
Publicado: (2010) -
A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor.
por: Veale, D., et al.
Publicado: (1988)